C4 Therapeutics (CCCC) Stock Price, News & Analysis

Company Overview

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines that selectively eliminate disease-causing proteins. The company uses targeted protein degradation, an approach designed to direct the body’s natural cellular machinery to identify and remove specific proteins that contribute to cancer and other diseases.

C4 Therapeutics’ proprietary TORPEDO platform is used to discover and develop small-molecule protein degraders. Its research and development programs have included therapies aimed at targets implicated in blood cancers, solid tumors and genetically defined cancers, including programs directed at IKZF1/3, BRD9 and mutant BRAF. The company has also pursued collaborations intended to apply targeted protein degradation to additional therapeutic areas.

Founded in 2015, C4 Therapeutics is headquartered in Watertown, Massachusetts. The company conducts its research primarily in the United States and has worked with international pharmaceutical partners to advance selected discovery and development programs. Andrew J. Hirsch serves as president and chief executive officer.

Key Stats

• Today's Range: $2.75 to $3.06
• 50-Day Range: $2.78 to $4.26
• 52-Week Range: $1.69 to $5.17
• Volume: 3.82 million shs
• Average Volume: 2.24 million shs
• Market Capitalization: $342.02 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.50
• Consensus Rating: Moderate Buy

C4 Therapeutics Stock Analysis - MarketRank™

C4 Therapeutics scored higher than 36% of companies evaluated by MarketBeat, and ranked 729th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

C4 Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

C4 Therapeutics has a consensus price target of $8.50, representing about 205.8% upside from its current price of $2.78.

Amount of Analyst Coverage

C4 Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for C4 Therapeutics are expected to decrease in the coming year, from ($0.81) to ($0.95) per share.

Price to Book Value per Share Ratio

C4 Therapeutics has a P/B Ratio of 1.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

34.78% of the float of C4 Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

C4 Therapeutics has a short interest ratio ("days to cover") of 17.65, which indicates bearish sentiment.

Change versus previous month

Short interest in C4 Therapeutics has recently increased by 0.51%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

C4 Therapeutics does not currently pay a dividend.

Dividend Growth

C4 Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 0.68

News Sentiment

C4 Therapeutics has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for C4 Therapeutics this week, compared to 2 articles on an average week.

Search Interest

5 people have searched for CCCC on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.

MarketBeat Follows

3 people have added C4 Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, C4 Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.60% of the stock of C4 Therapeutics is held by insiders.

Percentage Held by Institutions

78.81% of the stock of C4 Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 10/13/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CCCC
• CIK: 1662579
• Web: www.c4therapeutics.com
• Phone: 617-231-0700
• Fax: N/A
• Employees: 104
• Year Founded: 2015

Price Target and Rating

• Average Price Target for C4 Therapeutics: $8.50
• High Price Target: $10.00
• Low Price Target: $7.00
• Potential Upside/Downside: +205.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.00)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$104.99 million
• Net Margins: -289.44%
• Pretax Margin: -289.09%
• Return on Equity: -45.45%
• Return on Assets: -30.90%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.45
• Quick Ratio: 5.45

Sales & Book Value

• Annual Sales: $35.95 million
• Price / Sales: 9.51
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.65 per share
• Price / Book: 1.05

Miscellaneous

• Outstanding Shares: 123,030,000
• Free Float: 116,136,000
• Market Cap: $342.02 million
• Optionable: Optionable
• Beta: 3.07